Syndromic Panel Enables Rapid Identification of Bloodstream Infections

A newly launched test addresses this need by identifying 20 gram-positive bacterial and fungal targets and 10 antimicrobial resistance markers directly from positive blood cultures and colonies, with results in about one hour.

QIAGEN has introduced the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel, expanding its syndromic testing menu into bloodstream infections. The introduction coincides with the ESCMID Global 2026 Congress in Munich on April 17 from 21, where the company is highlighting its infectious disease portfolio alongside technologies that support laboratory workflows, clinical decision-making, and the development of Laboratory Developed Tests (LDTs). The launch marks entry into a new clinical application area for the QIAstat-Dx platform.

The BCID GPF Plus AMR Panel enables detection of 20 gram-positive and fungal (GPF) pathogen targets and 10 antimicrobial resistance (AMR) markers from positive blood cultures and pure colonies. Results are delivered in about one hour to support rapid treatment decisions. The QIAstat-Dx system integrates sample preparation, molecular testing, and data analysis into a single workflow to streamline operations within routine clinical laboratories.

The panel is CE-IVDR-certified. The launch extends the QIAstat-Dx portfolio beyond respiratory, gastrointestinal, and meningitis/encephalitis applications into bloodstream infection testing. QIAstat-Dx systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025. Additional panels are in development, including those targeting gram-negative pathogens, broadening coverage of bloodstream infection etiologies and resistance determinants.

“Rapid identification of pathogens and resistance markers is important in bloodstream infections, where treatment decisions often need to be made quickly,” said Nadia Aelbrecht, Vice President, Head of Infectious Diseases at QIAGEN.

“With this launch, we are extending the QIAstat-Dx portfolio into bloodstream infection testing and giving laboratories a new option to generate clinically relevant results from positive blood cultures and colonies. We plan to further expand this offering with additional panels in development, including those targeting gram-negative pathogens,” said Aelbrecht.